The Role of Vasodilating Agents in the Treatment of Chronic Heart Failure

Gunnar, Rolf M.
August 1980
Angiology;Aug1980, Vol. 31 Issue 8, p526
Academic Journal
The article presents information on the role of vasodilating agents in the treatment of chronic heart failure. The compensatory mechanisms which appear in patients with cardiac failure are not released early enough, and, therefore, become part of the problem rather than part of the solution. As blood flow falls, the renin-angiotensin system is activated and angiotensin causes constriction of the peripheral arteries, thus increasing the work of the heart. The determinants of myocardial oxygen consumption are intramyocardial wall tension, which is made up of systolic pressure and ventricular volume, myocardial contractility, which is really related to sympathetic drive and the heart rate, and the duration of systole, which again relates to heart rate and the systolic ejection period.


Related Articles

  • CPR's smarter sister? Gutfeld, G.; Meyers, M. // Prevention;Jun91, Vol. 43 Issue 6, p15 

    Considers a simple variation of cardiopulmonary resuscitation (CPR) which may double the survival rate of cardiac arrest victims. Uses `counterpulsation' or pressure on the upper abdomen to boost blood flow to the heart; Technique is called `Interposed Abdominal Counterpulsation.'

  • Therapeutic Potential of Vasopressin Receptor Antagonists. Ali, Farhan; Guglin, Maya; Vaitkevicius, Peter; Ghali, Jalal K. // Drugs;2007, Vol. 67 Issue 6, p847 

    Arginine vasopressin (AVP) is a neuropeptide hormone that plays an important role in circulatory and sodium homeostasis, and regulating serum osmolality. Several clinical conditions have been associated with inappropriately elevated levels of AVP including heart failure, cirrhosis of the liver...

  • Antioxidant treatment for heart failure: friend or foe? M. J. Thomson; M. P. Frenneaux; J. C. Kaski // QJM: An International Journal of Medicine;May2009, Vol. 102 Issue 5, p305 

    Increasing studies demonstrate a pivotal role for oxidant stress in the pathophysiology of heart failure (HF). Recent meta-analyses also reveal the potential pitfall of a mono-dimensional antioxidant approach. This review article summarizes the main biological pathways involved in oxidant stress...

  • Levosimendan: a decade of experience in Europe built on years of evidence. Parissis, John; Toller, Wolfgang; Franco, Fatima; Delgado, Juan F.; Danou, Fotini; Llorens-Soriano, Pere; Karpati, Peter C.J.; Nieminen, Markku S.; Mebazaa, Alexandre; Follath, Ferenc // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 2, p234 

    Abstract: Recent European Society of Cardiology''s (ESC) guidelines on the diagnosis and treatment of acute heart failure (AHF), suggest that an essential target in the management of these patients is to improve symptoms within hours, which should persist until hospital release, also protecting...

  • congestion.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p508 

    A definition of the term "congestion," which refers to an excessive amount of blood flow to a part or from dilatation of blood vessels, is presented.

  • Mayo Clinic Researchers Discover Gene Mutations That 'Ignore' Stress, Lead to Heart Failure.  // Ascribe Newswire: Medicine;4/6/2004, p28 

    Mayo Clinic researchers have discovered genetic mutations in heart patients that make them vulnerable to heart failure because they produce an abnormal protein that can't decode stress messages from the body. Research team leader Andre Terzic, a specialist in cardiac biology, describes the work...

  • Randomised trial of telephone intervention in chronic heart failure: DIAL trial. Grancelli, H. // BMJ: British Medical Journal (International Edition);8/20/2005, Vol. 331 Issue 7514, p425 

    Objective: To determine whether a centralised telephone intervention reduces the incidence of death or admission for worsening heart failure in outpatients with chronic heart failure. Design: Multicentre randomised controlled trial. Setting: 51 centres in Argentina (public and private hospitals...

  • β blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure. Khan, W.; Deepak, S. M.; Coppinger, T.; Waywell, C.; Borg, A.; Harper, L.; Williams, S. G.; Brooks, N. H. // Heart;Dec2006, Vol. 92 Issue 12, p1856 

    The article provides information on the effect of βblocker treatment associated with improvement in renal function and anemia in patients with heart failure. It has been explained that chronic renal impairment and anemia are common comorbidities associated with congestive heart failure. This...

  • Effects of spironolactone on endothelial function converting enzyme activity, prognostic markers in patients with mild already taking optimal treatment function, vascular and other heart failure. Macdonald, J. E.; Kennedy, N.; A. D. Struthers // Heart;Jul2004, Vol. 90 Issue 7, p765 

    Objectives: To examine whether the favourable effects on endothelial function, vascular angiotensin converting enzyme (ACE) activity, cardiac remodelling, autonomic function, and QT intervals of spironolactone in combination with ACE inhibitor also occur in patients with New York Heart...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics